These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 16516670)

  • 1. Clinical experience with denileukin diftitox (ONTAK).
    Foss F
    Semin Oncol; 2006 Feb; 33(1 Suppl 3):S11-6. PubMed ID: 16516670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Denileukin diftitox: a concise clinical review.
    Eklund JW; Kuzel TM
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):33-8. PubMed ID: 15757436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing denileukin diftitox (Ontak) therapy.
    Duvic M; Talpur R
    Future Oncol; 2008 Aug; 4(4):457-69. PubMed ID: 18684057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Denileukin diftitox as novel targeted therapy for lymphoid malignancies.
    Wong BY; Gregory SA; Dang NH
    Cancer Invest; 2007 Sep; 25(6):495-501. PubMed ID: 17882663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma.
    Talpur R; Jones DM; Alencar AJ; Apisarnthanarax N; Herne KL; Yang Y; Duvic M
    J Invest Dermatol; 2006 Mar; 126(3):575-83. PubMed ID: 16410787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma.
    Dang NH; Hagemeister FB; Pro B; McLaughlin P; Romaguera JE; Jones D; Samuels B; Samaniego F; Younes A; Wang M; Goy A; Rodriguez MA; Walker PL; Arredondo Y; Tong AT; Fayad L
    J Clin Oncol; 2004 Oct; 22(20):4095-102. PubMed ID: 15353540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders.
    Turturro F
    Expert Rev Anticancer Ther; 2007 Jan; 7(1):11-7. PubMed ID: 17187516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Denileukin diftitox as novel targeted therapy in non-Hodgkin's lymphoma.
    Walker PL; Dang NH
    Clin J Oncol Nurs; 2004 Apr; 8(2):169-74. PubMed ID: 15108419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Denileukin diftitox: a novel immunotoxin.
    Manoukian G; Hagemeister F
    Expert Opin Biol Ther; 2009 Nov; 9(11):1445-51. PubMed ID: 19817678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. De novo maintenance therapy with denileukin diftitox (Ontak) in a patient with peripheral T-cell lymphoma is associated with prolonged remission.
    Wong BY; Ma Y; Fitzwilson R; Dang NH
    Am J Hematol; 2008 Jul; 83(7):596-8. PubMed ID: 18383317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Denileukin diftitox.
    Figgitt DP; Lamb HM; Goa KL
    Am J Clin Dermatol; 2000; 1(1):67-72; discussion 73. PubMed ID: 11702307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologic correlates of response and survival in patients with cutaneous T-cell lymphoma treated with denileukin diftitox.
    Chin KM; Foss FM
    Clin Lymphoma Myeloma; 2006 Nov; 7(3):199-204. PubMed ID: 17229335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DAB(389)IL-2 (denileukin diftitox, ONTAK): other potential applications.
    LeMaistre CF
    Clin Lymphoma; 2000 Nov; 1 Suppl 1():S37-40. PubMed ID: 11707862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upfront denileukin diftitox as in vivo regulatory T-cell depletion in order to enhance vaccination effects in a canine allogeneic hematopoietic stem cell transplantation model.
    Knueppel A; Lange S; Altmann S; Sekora A; Knuebel G; Vogel H; Lindner I; Freund M; Junghanss C
    Vet Immunol Immunopathol; 2012 Jan; 145(1-2):233-40. PubMed ID: 22173275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma.
    Olsen E; Duvic M; Frankel A; Kim Y; Martin A; Vonderheid E; Jegasothy B; Wood G; Gordon M; Heald P; Oseroff A; Pinter-Brown L; Bowen G; Kuzel T; Fivenson D; Foss F; Glode M; Molina A; Knobler E; Stewart S; Cooper K; Stevens S; Craig F; Reuben J; Bacha P; Nichols J
    J Clin Oncol; 2001 Jan; 19(2):376-88. PubMed ID: 11208829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regression of extranodal natural killer/T-cell lymphoma, nasal type with denileukin diftitox (Ontak) and bexarotene (Targretin): report of a case.
    Kerl K; Prins C; Cerroni L; French LE
    Br J Dermatol; 2006 May; 154(5):988-91. PubMed ID: 16634908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma.
    Attia P; Maker AV; Haworth LR; Rogers-Freezer L; Rosenberg SA
    J Immunother; 2005; 28(6):582-92. PubMed ID: 16224276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lethal vascular leak syndrome after denileukin diftitox administration to a patient with cutaneous gamma/delta T-cell lymphoma and occult cirrhosis.
    Avarbock AB; Loren AW; Park JY; Junkins-Hopkins JM; Choi J; Litzky LA; Rook AH
    Am J Hematol; 2008 Jul; 83(7):593-5. PubMed ID: 18335564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Denileukin diftitox.
    Saxon M
    Clin J Oncol Nurs; 2000; 4(6):289, 293. PubMed ID: 11899329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma.
    Foss FM
    Clin Lymphoma; 2000 Sep; 1(2):110-6; discussion 117. PubMed ID: 11707818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.